ImageFIRST Announces New Linen Risk Assessment for Healthcare Providers

ImageFirst reports the Linen Risk Assessment offers a comprehensive analysis of a healthcare provider’s linen program.

It is designed to help a provider understand if their linen is compliant with infection prevention recommendations and regulations. If not, the resulting customized report will highlight potential areas the facility can improve on.

ImageFIRST is offering its Linen Risk Assessment to medical facilities in the U.S., regardless of whether they are currently an ImageFIRST customer.

With healthcare now placing a greater emphasis on infection ​prevention more than ever, medical providers are looking​ for ways to minimize the spread of COVID-19 and sanitize ​common points of infection – including linen. ​The Joint Commission, an organization dedicated to continuous improvement in healthcare, recommends conducting a risk assessment to identify actual and potential risks. ​

Hygienically clean laundry is crucial to minimize the spread ​of pathogens according to the Centers for Disease Control ​and Prevention (CDC), the Association of periOperative ​Registered Nurses (AORN) and the Healthcare Laundry ​Accreditation Council (HLAC). ​​However, not all laundering is effective at removing bacteria. ​

The CDC states that dry cleaning is ineffective in reducing bacteria and viruses on linens, and that microorganisms can survive home laundering. OSHA regulations even prohibit home laundering of personal protective apparel such as lab coats, isolation gowns and scrubs. The CDC specifies that detergents used for healthcare laundry should be registered by the U.S. Environmental Protection Agency (EPA) to ensure adequate cleaning. ​

ImageFIRST offers fully-managed linen and apparel rental and laundry programs with comprehensive infection prevention processes that exceed standards and a wash process that is effective against COVID-19. Their laundering processes meet or exceed OSHA, CDC, HLAC requirements, and comply with The Joint Commission requirements.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”